Treatment of Anemia in Sjögren's Syndrome

Introduction to Treatment

The American College of Rheumatology recommends treating the underlying Sjögren's syndrome with glucocorticoids as first-line therapy, followed by immunosuppressive agents as steroid-sparing options, and reserving rituximab for severe refractory cases; do not give iron supplementation unless biochemically proven iron deficiency exists 1, 2

The European League Against Rheumatism (EULAR) suggests assessing disease activity using the ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) to guide treatment intensity 2, 3

The American College of Rheumatology recommends starting with glucocorticoids at the minimum effective dose (typically 0.5-1.0 mg/kg/day) for the shortest duration necessary to control active systemic disease 1, 2, 3
Consider methylprednisolone pulses for severe cases 1
The European League Against Rheumatism (EULAR) suggests tapering glucocorticoids as quickly as possible to avoid long-term complications 2, 3
Use cyclophosphamide, azathioprine, methotrexate, leflunomide, or mycophenolate as glucocorticoid-sparing agents 1, 2, 3, 4
No head-to-head comparisons exist between these agents, so selection should be based on patient comorbidities and side effect profiles 1

Rituximab (1 g administered 15 days apart, two doses) may be considered for severe, refractory systemic disease 1, 2, 3, 4
Best indications include vasculitis, cryoglobulinemia-associated complications, or lymphoma 1
Belimumab is an alternative B-cell targeted therapy that has shown efficacy in some refractory cases 1

Do NOT give iron supplementation unless iron deficiency is biochemically proven (low ferritin in the context of Sjögren's), as repeated transfusions can lead to iron overload 5
Avoid prolonged glucocorticoid use without steroid-sparing strategies 2, 3
Red blood cell transfusions are reserved for symptomatic severe anemia while awaiting response to immunosuppressive therapy 5

Monitor for treatment-related complications: infection risk with immunosuppression, bone marrow suppression with cyclophosphamide or azathioprine 1
Ensure influenza and pneumococcal vaccination before starting immunosuppressive therapy 2

Treating anemia symptomatically without addressing the underlying autoimmune process is not recommended 2